Trials / Completed
CompletedNCT01826916
EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema
EDEMA2: An Open-Label Study to Assess the Efficacy and Tolerability of Repeated Doses of DX-88 (Recombinant Plasma Kallikrein Inhibitor) in Patients With Hereditary Angioedema
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 77 (actual)
- Sponsor
- Shire · Industry
- Sex
- All
- Age
- 10 Years
- Healthy volunteers
- Not accepted
Summary
EDEMA2 is an open-label, Phase 2 dose-ranging study designed to assess the safety and efficacy of repeated dosing of DX-88 (recombinant plasma kallikrein inhibitor) in Patients with Hereditary Angioedema.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DX-88 (ecallantide) | solution for injection 10 mg/mL |
Timeline
- Start date
- 2003-11-01
- Primary completion
- 2005-12-01
- Completion
- 2006-01-01
- First posted
- 2013-04-09
- Last updated
- 2021-05-18
Source: ClinicalTrials.gov record NCT01826916. Inclusion in this directory is not an endorsement.